Epicrispr Biotechnologies
Develops programmable epigenetic medicines to treat genetic diseases like FSHD
$90MSeries C
Role not disclosedActivity from announced rounds
Develops programmable epigenetic medicines to treat genetic diseases like FSHD
AI-driven platform that simulates clinical trials to predict outcomes before patient enrollment